Revenue $1.71B, up 29.6% on a year earlier. Product revenue, net $1.68B, up 29.0%. Collaboration revenue $25.28M, up 91.1%. Diluted EPS $0.16 against $0.06.
| Q2 FY26 | Q1 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $1.71B | $1.51B | $1.32B | +29.6% |
| Operating income | $325.05M | $249.90M | $87.89M | +269.9% |
| Net income | $237.01M | $227.36M | $94.32M | +151.3% |
| Diluted EPS | $0.16 | $0.15 | $0.06 | |
| Operating cash flow | $462.82M | $201.34M | $263.60M | +75.6% |
| Capital expenditures | -$27.48M | -$40.79M | -$43.83M | |
| Free cash flow | $435.34M | $160.55M | $219.77M | +98.1% |
| Q2 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|
| Product revenue, net | $1.68B | $1.30B | +29.0% |
| Collaboration revenue | $25.28M | $13.22M | +91.1% |
| U.S. BRUKINSA sales | $893.00M | $684.00M | +30.6% |
| TEVIMBRA global sales | $229.00M | $194.00M | +18.0% |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “BeOne Medicines (ONC) Q2 FY26 earnings: results and KPIs”, stockatlas.com/companies/ONC/earnings/2026-q2/, data as of 3 November 2026. Links to this page are welcome.
